Mylan NV, bruised by its acrimonious and ultimately unsuccessful bid to buy Perrigo Co., is likely to find itself now competing with the drugmaker for other assets.
Both companies may look to buy Impax Laboratories Inc., a generic-drug maker from Hayward, California; Stada Arzneimittel AG, a German maker of off-patent medicines; or Taro Pharmaceutical Industries Ltd. of Israel, said Elizabeth Krutoholow, a Bloomberg Intelligence analyst in New York. All of them have over-the-counter products, making them attractive targets.
Read the full story at Bloomberg, by Makiko Kitamura
Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
